Strong beat from Resmed, ahead of consensus across the board.

The key bits, strong revenue growth (+7%) and a material recovery in gross margin (+240 bps), with a variety of factors contributing (everything from reduced freight costs, manufacturing improvements, favourable product mix and higher prices).

A key worry/fear/concern from the market has been GLP-1, weight loss drugs; our contention has been that these are complements, at least in the short to medium run. On RMD’s numbers, those on GLP-1 have a 10.5% higher propensity to start PAP therapy.

Debt came down by $220M in the quarter, and will likely keep coming down given the material cashflow generation. ND/EBITDA is <1x in any case, which is very low.

Overall, strong result.

Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.

This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.

Please note that past performance is not a reliable indicator of future performance.

General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.

Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.